The Global Recombinant Human Erythropoietin for Injection market was valued at USD 9,168 million in 2023, and it is anticipated to reach approximately USD 15,754.16 million by 2032, growing at a CAGR of 6.20% over the forecast period. This robust growth is attributed to the increasing prevalence of anemia due to chronic diseases, rising demand for biosimilars, and expanding...